DXCM - 2 Unstoppable Growth Stocks to Buy in 2023 and Beyond
Last year's bear market made many victims among even the most prominent corporations although growth stocks fared even worse than other categories of equities. But some growth-oriented companies managed to buck the trend. Among this small group of outperformers are two healthcare leaders: biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) and medical device expert DexCom (NASDAQ: DXCM) .
These two stocks aren't one-hit wonders, either. There are good reasons why they performed as well as they did in 2022, and there are equally solid reasons to think they can produce similarly robust returns in the long run. Let's consider why Vertex Pharmaceuticals and DexCom are excellent stocks to buy.
Vertex Pharmaceuticals is entering an important stretch. Over the past 10 years, the company has generated growing revenue and earnings thanks to its medicines that treat cystic fibrosis (CF), a rare genetic condition. Now, the drugmaker looks to be on the verge of marketing a product in a different therapeutic area.
For further details see:
2 Unstoppable Growth Stocks to Buy in 2023 and Beyond